NASDAQ:HSTO - Histogen Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $4.00
  • Forecasted Upside: 374.27 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$0.84
▼ -0.01 (-1.17%)

This chart shows the closing price for HSTO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Histogen Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for HSTO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for HSTO

Analyst Price Target is $4.00
▲ +374.27% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Histogen in the last 3 months. The average price target is $4.00, with a high forecast of $4.00 and a low forecast of $4.00. The average price target represents a 374.27% upside from the last price of $0.84.

This chart shows the closing price for HSTO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 1 contributing investment analysts is to buy stock in Histogen.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/12/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/12/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/10/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/8/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/6/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/7/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/6/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/5/2021

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/4/2021Canaccord GenuityLower Price TargetBuy$5.00 ➝ $4.00High
3/4/2021Canaccord GenuityInitiated CoverageBuy$5.00High
(Data available from 8/5/2016 forward)
Histogen logo
Histogen, Inc. engages in the development of potential first-in-class restorative therapeutics that ignite the body's natural process to repair and maintain healthy biological function. It focuses in Human Multipotent Cell Conditioned Media, Human Extracellular Matrix, and Hair Stimulating Complex. The company was founded by Steven J. Mento and Gail K. Naughton on July 13, 2005 and is headquartered in San Diego, CA.
Read More

Today's Range

Now: $0.84
Low: $0.84
High: $0.86

50 Day Range

MA: $0.95
Low: $0.81
High: $1.13

52 Week Range

Now: $0.84
Low: $0.75
High: $3.59

Volume

407,804 shs

Average Volume

1,358,933 shs

Market Capitalization

$30.15 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.01

Frequently Asked Questions

What sell-side analysts currently cover shares of Histogen?

The following equities research analysts have issued stock ratings on Histogen in the last twelve months: Canaccord Genuity.
View the latest analyst ratings for HSTO.

What is the current price target for Histogen?

1 Wall Street analysts have set twelve-month price targets for Histogen in the last year. Their average twelve-month price target is $4.00, suggesting a possible upside of 374.3%. Canaccord Genuity has the highest price target set, predicting HSTO will reach $4.00 in the next twelve months. Canaccord Genuity has the lowest price target set, forecasting a price of $4.00 for Histogen in the next year.
View the latest price targets for HSTO.

What is the current consensus analyst rating for Histogen?

Histogen currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe HSTO will outperform the market and that investors should add to their positions of Histogen.
View the latest ratings for HSTO.

What other companies compete with Histogen?

How do I contact Histogen's investor relations team?

Histogen's physical mailing address is 16745 W. Bernardo Dr. Suite 250, San Diego CA, 92127. The company's listed phone number is (858) 526-3100 and its investor relations email address is [email protected] The official website for Histogen is www.histogen.com.